Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners
Tribe Technology set to deliver healthy pipeline of orders from Tier-One minersView Video
Andrada Mining acquisition elevates the miner to emerging mid-tier status
Andrada Mining acquisition elevates the miner to emerging mid-tier statusView Video

Latest Share Chat

Pin to quick picksSanofi Share News (SAN.PA)

Share Price Information for Sanofi (SAN.PA)

Euronext Paris
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 89.94
Bid: 93.35
Ask: 93.36
Change: 0.08 (0.089%)
Spread: 0.01 (0.011%)
Open: 90.23
High: 90.59
Low: 89.73
Prev. Close: 89.86
SAN.PA Live PriceLast checked at -
  • This share is an international stock.

Watchlists are a member only feature

Login to your account

European shares slip overall but German blue-chips hit record high

Fri, 28th Jul 2023 17:31

STOXX 600 dips 0.2% but posts weekly gains

*

Germany's DAX hits record high

*

BOJ policy tweak lifts European yields

*

Capgemini slides as Q2 growth slows

July 28 (Reuters) - European shares retreated from multi-month highs on Friday after a mixed bag of earnings and a surprise Bank of Japan policy tweak, but German blue-chips bucked the trend to close at a record high on signs of cooling inflation.

The pan-European STOXX 600 index ended 0.2% lower after closing at its highest level in nearly 1-1/2 years on Thursday when the European Central Bank hiked interest rates as expected but raised the possibility of a pause in September.

Rattling investor nerves, the BoJ made its yield curve control policy more flexible and loosened its defence of a long-term interest rate cap, in moves seen as a prelude to an eventual shift away from the massive monetary stimulus.

"We have the last of the accommodative central banks moving away from accommodative policies," said Steve Sosnick, chief strategist at Interactive Brokers.

"The fear of this BOJ move was because it can really affect hedge funds' carry trade...there was a fear that this could really spiral out from Japan yields (but) it hasn't happened."

Germany's DAX index hit an intraday record and held on to most of the gains to close 0.39% higher after data showed inflation resumed a downward trend in Europe's largest economy.

However, separate data showed the economy stagnated in the second quarter of 2023, missing forecasts for modest growth

Elsewhere, Spanish consumer prices rose by a more than anticipated 2.3% in the 12 months through July.

Despite Friday's weakness, the benchmark STOXX 600 notched up a third straight week of gains, on hopes that the Federal Reserve and the ECB are nearly done hiking interest rates.

Tech stocks and miners were among the week's top gainers, adding 3.6% and 3.4% respectively.

Hermes rose 3.9% as sales at the Birkin bag maker accelerated in the second quarter, while AstraZeneca advanced 3.3% after reporting forecast-beating profit and sales.

French drugmaker Sanofi slipped 2.9% as quarterly sales fell short of estimates, and French IT consulting group Capgemini tumbled 7.0% on a bigger-than-expected slowdown in second-quarter growth.

Austrian sensor maker AMS Osram jumped 18.5% after the company presented a strategic re-alignment of the group and reported second-quarter results in line with its expectations.

Pan-European stock and derivatives exchange Euronext climbed 7.4%, boosted by the launch of a 200-million-euro ($219.88 million) share buyback programme. (Reporting by Sruthi Shankar, Amruta Khadekar and Shristi Achar A in Bengaluru; Editing by Kirsten Donovan)

More News
24 Feb 2023 15:10

First Zantac cancer risk trial in Calif. postponed five months

Feb 23 (Reuters) - The first scheduled trial over claims that GSK Plc's heartburn drug Zantac caused cancer, which had been set to begin Monday, has been postponed by five months.

Read more
16 Feb 2023 23:17

Judge weighs key evidence ahead of first Zantac cancer trial

Feb 16 (Reuters) - Lawyers for a man who alleges he developed bladder cancer after taking GSK Plc's heartburn drug Zantac urged a California judge on Thursday to allow expert testimony linking the drug to the illness at an upcoming trial.

Read more
16 Feb 2023 19:38

Judge to weigh key evidence ahead of first Zantac cancer trial

Feb 16 (Reuters) - GSK Plc is expected to urge a California judge on Thursday to limit what expert testimony jurors can hear in the first trial over claims that the company's heartburn drug Zantac caused cancer.

Read more
13 Feb 2023 17:19

European shares rise as defence stocks rally, focus on U.S. inflation data

STOXX 600 ends up 0.9%

*

Read more
3 Feb 2023 17:27

European shares log weekly gains, UK's blue-chip index hits record high

STOXX 600 up 0.3%, logs gains for second straight week

*

Read more
3 Feb 2023 11:49

Sanofi forecasts moderate profit growth on Dupixent demand

Sees "low single digit" percentage core EPS growth, FX adjusted

*

Read more
31 Jan 2023 12:26

Share buybacks in Europe as significant as in U.S.

STOXX 600 down around 1%

*

Read more
31 Jan 2023 11:30

Banks: six reasons to be overweight

STOXX 600 down 1%

*

Read more
31 Jan 2023 09:15

STOXX slides

STOXX 600 down 0.5%

*

Read more
31 Jan 2023 07:36

European shares seen lower

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at

EUROPEAN SHARES SEEN LOWER (0730 GMT)

Read more
31 Jan 2023 06:56

Mind the gap

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at

MIND THE GAP (0656 GMT)

Read more
30 Jan 2023 20:27

Drugmakers prevail in dispute over U.S. discount drug program

Jan 30 (Reuters) - Drug manufacturers can limit healthcare providers' use of outside pharmacies for dispensing drugs under a federal drug discount program, a federal appeals court ruled Monday.

Read more
30 Jan 2023 17:42

Drugmakers prevail in dispute over U.S. discount drug program

Jan 30 (Reuters) - Drug manufacturers can limit healthcare providers' use of outside pharmacies for dispensing drugs under a federal drug discount program, a federal appeals court ruled Monday.

Read more
4 Jan 2023 10:51

Sanofi sees decision on Zantac dispute with Boehringer in Q1 at earliest

Arbitration decision initially expected by end of 2022

*

Read more
12 Dec 2022 21:46

Amgen dives deeper into rare disease drugs with $27.8 bln Horizon deal

Dec 12 (Reuters) - Amgen Inc on Monday agreed to buy Horizon Therapeutics Plc in a deal valued at $27.8 billion, fortifying its rare diseases portfolio in the biggest buyout in the sector this year.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.